Lageman, Senne B. https://orcid.org/0009-0001-8516-7429
Jolly, Amy https://orcid.org/0000-0002-7413-9772
Sahi, Nitin https://orcid.org/0000-0002-0403-916X
Prados, Ferran https://orcid.org/0000-0002-7872-0142
Kanber, Baris https://orcid.org/0000-0003-2443-8800
Eshaghi, Arman https://orcid.org/0000-0002-6652-3512
Tur, Carmen https://orcid.org/0000-0003-1849-3184
Eierud, Cyrus https://orcid.org/0000-0002-9942-676X
Calhoun, Vince D. https://orcid.org/0000-0001-9058-0747
Schoonheim, Menno M. https://orcid.org/0000-0002-2504-6959
Chard, Declan T. https://orcid.org/0000-0003-3076-2682
Funding for this research was provided by:
Multiple Sclerosis Society
UCLH Biomedical Research Centre (NIHR (National Institute for Health, Care Research) Biomedical Research Centre at University College London, NIHR (National Institute for Health, Care Research) Biomedical Research Centre at University College London, NIHR (National Institute for Health, Care Research) Biomedical Research Centre at University College London)
Article History
Received: 20 June 2024
Revised: 5 October 2024
Accepted: 6 October 2024
First Online: 15 January 2025
Declarations
:
: N.S. has been a clinical research fellow in a post supported by Merck (supervised by D.C.) and subsequently by MRC (MR/W019906/1). D.C. is a consultant for Hoffmann-La Roche. In the last 3 years, he has been a consultant for Biogen, has received research funding from Hoffmann-La Roche, the International Progressive MS Alliance, the MS Society, the Medical Research Council, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, and has been a speaker’s honorarium from Novartis. He co-supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck.
: This study had research ethics committee approval (09/H0716/77).
: All participants in the study gave written informed consent.